EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

THC Biomed Intl Ltd (THCBF) fair value: what the stock is really worth

As of Sep 29, 2026: fair value of THC Biomed Intl Ltd $0.00, price $0.00, upside -0.1%, quality 46 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US

TB THC Biomed Intl Ltd logo Thin data Sep 27, 2026

THC Biomed Intl Ltd

THCBF · US

Low PriorityFair Value upside is limited and quality is weak.

·Fair value $0.0010 · Fairly valued (−0.1%)
!Quality 46/100
!Mixed Growth (revenue 3y +18.0 %/yr)
!Loss-making · -164.8% net margin (TTM)
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 9/100
!Evidence only low, so the estimate is less certain
Watch THC Biomed Intl Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.1220 $0.0010 Fair Value $0.0010 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.

How to read this chart

60‑month range $0.0010 – $0.1220 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens above the $0.0010 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.

Follow THC Biomed Intl in your weekly email

Every Wednesday you see whether THC Biomed Intl is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

THC Biomed Intl Ltd. engages in the research, development, production, and sale of cannabis products in Canada. The company offers cannabis consumables, including beverage drinks, gummies, baked goods, pre-rolls, sticks, and clones under the THC Kiss brand name; and genetic strains under the THC BioMed brand name.

Show more

THC Biomed Intl Ltd. engages in the research, development, production, and sale of cannabis products in Canada. The company offers cannabis consumables, including beverage drinks, gummies, baked goods, pre-rolls, sticks, and clones under the THC Kiss brand name; and genetic strains under the THC BioMed brand name. It also provides dry flowers under the Smoke That Thunders brand name; buds under the Always Hi brand name; and transport solution for young live plants under the Cloneshipper brand name. The company was founded in 2012 and is based in Kelowna, Canada.

Stock analysis

THC Biomed Intl Ltd (THCBF) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010, so the stock looks roughly fairly valued today (gap 0.1%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: $0.0010 (bear) to $0.0010 (bull), the price of $0.0010 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

THC Biomed Intl Ltd reported revenue of $2.4M in FY2022 versus $925K in FY2018, a compound +27.6%/yr. Reported net income was −$3.1M in FY2022.

Key figures

Market cap $164K · P/S ratio 0.07 · EPS (TTM) $−0.0100 · Net margin −125% · Return on equity −56.5% · Return on assets (EBIT) −18.9% · Operating margin −243% · Revenue (TTM) $2.2M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades at its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at 0%, THCBF screens cheaper than that median.

Fair Value models

Bear $0.0010 Fair Value $0.0010 Bull $0.0010
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0007 $0.0010 $0.0013 54
All 1 models by family
Asset-Based
NCAV (Graham) $0.0007 $0.0010 $0.0013 54

Open the full fair value analysis →

Notify me when THCBF reaches fair value

Put THCBF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 46/100

Of which business quality 44 · Market factors (momentum, volatility) 35

Profitability 0
Margins and returns on capital today
Quality Growth 65
Are margins and returns improving?
Cashflow 27
Earnings quality: real cash, not paper profit
Fin. Strength 41
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 11
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 73
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 27/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−35.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.0%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,425.0% (2017) → −110.6% (2022)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2022 is a loss year, no rate is defined from a loss
not computed

Watch THCBF, get fair value alerts →

Compare THC Biomed Intl Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 599 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside −0.1% · Above median
Profitability
Return on assets −15.3% · Bottom 25%
Net margin (TTM) −164.8% · Bottom 25%
Growth and dividend
Revenue growth −22.1% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/S (TTM) 0.07× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)33 · sector 16
FUTURE (revenue growth)0 · sector 24
PAST (return on equity)0 · sector 27
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)0 · sector 30

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €134.45 €108.94 −19%
Takeda Pharmaceutical Company TAK $18.90 $11.45 −39%
Teva Pharmaceutical Industries Limited TEVA $39.31 $20.88 −47%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,852 ₹1,979 +7%
Galderma Group GALD CHF 163.00 CHF 110.32 −32%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥44.86 ¥49.35 +10%
Haleon plc HLN $9.26 $8.49 −8%
Sandoz Group SDZ CHF 71.16 CHF 40.32 −43%
Zoetis Inc ZTS $70.30 $110.50 +57%
Divi's Laboratories Limited DIVISLAB ₹9,620 ₹1,871 −81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

THC Biomed Intl Ltd · Fair Value
$0.0010 −0%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "THC Biomed Intl Ltd Fair Value". https://www.fairvalue-calculator.com/stock/THCBF

Frequently asked questions

Is THC Biomed Intl Ltd (THCBF) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0010 versus a price of $0.0010, about −0% upside (fairly valued).
What is the fair value of THCBF?
Our model-based fair value for THC Biomed Intl Ltd is $0.0010 (as of Sep 27, 2026), built from audited fundamentals. The current price: $0.0010.
What is the quality score of THCBF?
THC Biomed Intl Ltd has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for THC Biomed Intl Ltd (THCBF)?
Our model-based price target is the fair value of $0.0010 (as of Sep 27, 2026) from 1 valuation models. Cautious scenario $0.0010, optimistic scenario $0.0010. It is a calculation from audited fundamentals, not an analyst target.
What is the THC Biomed Intl Ltd stock forecast for 2026?
Our models put fair value at $0.0010, about −0% upside versus a price of $0.0010 (fairly valued). Cautious scenario $0.0010, optimistic scenario $0.0010. The calculation is refreshed regularly with new filings.
What is the revenue of THC Biomed Intl Ltd (THCBF)?
THC Biomed Intl Ltd reported trailing-twelve-month revenue of about $2.2M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of THC Biomed Intl Ltd (THCBF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For THC Biomed Intl Ltd it is $0.0010 per share (as of Sep 27, 2026), against a price of $0.0010. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is THC Biomed Intl Ltd stock overvalued or undervalued in 2026?
As of Sep 27, 2026, THCBF trades above its calculated fair value: price $0.0010, fair value $0.0010, a gap of about −0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of THCBF?
No. The price is what the market pays today ($0.0010); the fair value is what the company's own numbers justify ($0.0010). For THC Biomed Intl Ltd the two are $0.0000 per share apart. That gap is exactly why we show both numbers side by side.
How much is THC Biomed Intl Ltd worth?
The market values THC Biomed Intl Ltd at about $164K (market capitalisation, as of Sep 27, 2026). Per share that is $0.0010; our models calculate a fair value of $0.0010 per share.
What do the bullish and bearish scenarios say about THCBF?
Our models span a range for THC Biomed Intl Ltd: cautious scenario $0.0010, base $0.0010, optimistic $0.0010 per share (as of Sep 27, 2026, price $0.0010). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of THC Biomed Intl Ltd (THCBF)?
Balance-sheet figures for THC Biomed Intl Ltd (as of Sep 27, 2026): return on equity −56.5%, debt of 0.12 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is THCBF from its 52-week high?
THC Biomed Intl Ltd trades at $0.0010, at its 52-week high of $0.0010 and at the low of $0.0010 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0010 is for.
Which stocks are comparable to THC Biomed Intl Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is THC Biomed Intl Ltd stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0010, calculated fair value $0.0010 (−0%), Quality Score 46/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of THCBF calculated?
We run THC Biomed Intl Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0010, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. THC Biomed Intl Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of THC Biomed Intl Ltd (THCBF)?
The closing price on Sep 29, 2026 was $0.0010. Our model-based fair value is $0.0010, about −0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with THC Biomed Intl Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The models converge in a tight band ($0.0010 to $0.0010), unusually little disagreement for a valuation. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of THC Biomed Intl Ltd

How large is the market capitalisation of THC Biomed Intl Ltd (THCBF)?
The market capitalisation of THC Biomed Intl Ltd is $164K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of THC Biomed Intl Ltd (THCBF)?
The price-to-sales ratio of THC Biomed Intl Ltd is 0.07 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of THC Biomed Intl Ltd (THCBF)?
Earnings per share at THC Biomed Intl Ltd are $−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of THC Biomed Intl Ltd (THCBF)?
The net margin of THC Biomed Intl Ltd is −125% (fiscal year 2022). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of THC Biomed Intl Ltd (THCBF)?
The return on equity (ROE) of THC Biomed Intl Ltd is −56.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of THC Biomed Intl Ltd (THCBF)?
On an EBIT basis the return on assets of THC Biomed Intl Ltd is −18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of THC Biomed Intl Ltd (THCBF)?
The operating margin of THC Biomed Intl Ltd is −243% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at THC Biomed Intl Ltd (THCBF)?
Revenue at THC Biomed Intl Ltd is growing −22.1% versus a year earlier (3y avg +18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does THC Biomed Intl Ltd (THCBF) generate?
The free cash flow of THC Biomed Intl Ltd is −$2.0M (fiscal year 2022). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does THC Biomed Intl Ltd (THCBF) carry?
The net debt of THC Biomed Intl Ltd is $1.5M (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch THC Biomed Intl Ltd in the live analysis

One click puts THC Biomed Intl Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.